[Gonadotropin stimulation and in vitro fertilization following selective hypophyseal suppression by LH/RH analogs].
Out of 109 hMG stimulations for in vitro fertilization (IVF) 41 cycles (38%) had to be cancelled because of premature endogenous luteinization. Pretreatment with the LH/RH-agonist Buserelin induces selective pituitary suppression and prevents spontaneous LH-surge during hMG stimulation. The pharmacologic hypogonadotropism allows considerable flexibility with respect to the timing of starting gonadotropin stimulation and ovulation induction. In 74 Buserelin/hMG/IVF-cycles no premature luteinization occurred and all started stimulations yielded in follicular puncture. In addition increased oocyte recovery rate, significant higher fertilization rate and significant better pregnancy rate could be achieved as compared with hMG/IVF-cycles. In conclusion pharmacologic hypogonadotropism by administration of LH/RH-analogue reliably prevents endogenous luteinization and improves gonadotropin stimulation as well as IVF results.
D000328:Adult; D002064:Buserelin / Q000627:therapeutic use*; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D008596:Menotropins / Q000627:therapeutic use; D011379:Prognosis
D006063:Chorionic Gonadotropin; D008596:Menotropins; D002064:Buserelin
Gonadotropin-Stimulation und In-vitro-Fertilisation nach selektiver Hypophysen-Suppression durch LH/RH-Analogon.